Il-1 binding proteins

An isolated composition comprising an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein, when administered intravenously to a subject at a dose of about 4 mg/kg, the anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, exhibits:

• (a) an area under the curve (AUC) of between about 10 and 20 mgh/ml;
• (b) a volume of distribution of between about 75 and 95 mL/kg;
• (c) a half-life of between about 7 and about 13 days;
• or
• (d) a clearance rate of between about 0.1 and about 0.4 ml/h/kg.

An isolated composition comprising an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein, when administered intravenously to a subject at a dose of about 5 mg/kg, the anti-IL-1α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, exhibits:

• (a) an area under the curve (AUC) of between about 15 and 30 mgh/ml;
• (b) a volume of distribution of between about 45 and 75 mL/kg;
• (c) a half-life of between about 7 and about 13 days;
• or
• (d) a clearance rate of between about 0.1 and about 0.4 ml/h/kg.

An isolated composition comprising an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 5 mg/kg, the anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, exhibits:

• (a) an area under the curve (AUC) of between about 15 and about 30 mgh/ml;
• (b) a half-life of between about 10 and about 30 days;
• or
• (c) a peak concentration (Cmax) of between about 20 and about 40 μg/ml.

An isolated composition comprising an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 4 mg/kg, the anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, exhibits:

• (a) an area under the curve (AUC) of between about 3 and about 12 mgh/ml;
• (b) a half-life of between about 7 and about 20 days;
• or
• (c) a peak concentration (Cmax) of between about 10 and about 30 μg/ml.

An isolated composition comprising an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein, when administered subcutaneously to a subject at a dose of about 5 mg/kg, the anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, exhibits:

• (a) an area under the curve (AUC) of between about 15 and about 30 mgh/ml;
• (b) a half-life of between about 4 and about 15 days;
• or
• (c) a peak concentration (Cmax) of between about 40 and about 65 μg/ml.

A method of treating osteoarthritis in a subject comprising intravenously administering to the subject an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

• (a) an area under the curve (AUC) of between about 10 and 30 mgh/ml;
• (b) a volume of distribution of between about 45 and 105 mL/kg;
• (c) a half-life of between about 7 and about 13 days;
• or
• (d) a clearance rate of between about 0.1 and about 0.4 ml/h/kg,
• is achieved following administration of the anti-IL-1α/β dual variable domain immunoglobulin, or antigen-binding portion thereof to said subject, thereby treating osteoarthritis in the subject.

A method of treating pain in a subject comprising intravenously administering to the subject an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

• (a) an area under the curve (AUC) of between about 10 and 30 mgh/ml;
• (b) a volume of distribution of between about 45 and 105 mL/kg;
• (c) a half-life of between about 7 and about 13 days;
• or
• (d) a clearance rate of between about 0.1 and about 0.4 ml/h/kg,
• is achieved following administration of the anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof to said subject, thereby treating pain in the subject.

A method of treating osteoarthritis in a subject comprising subcutaneously administering to the subject an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

• (a) an area under the curve (AUC) of between about 3 and about 30 mgh/ml;
• (b) a half-life of between about 4 and about 30 days;
• or
• (c) a peak concentration (Cmax) of between about 10 and about 65 μg/ml,
• is achieved following administration of the anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof to said subject, thereby treating osteoarthritis in the subject.

A method of treating pain in a subject comprising subcutaneously administering to the subject an anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof, wherein at least one pharmacokinetic characteristic selected from the group consisting of:

• (a) an area under the curve (AUC) of between about 3 and about 30 mgh/ml;
• (b) a half-life of between about 4 and about 30 days;
• or
• (c) a peak concentration (Cmax) of between about 10 and about 65 μg/ml,
• is achieved following administration of the anti-IL-α/β dual variable domain immunoglobulin, or antigen-binding portion thereof to said subject, thereby treating pain in the subject.